Galactica Pharmaceuticals

Executive Summary

Galactica Pharmaceuticals is a preclinical-stage biopharmaceutical company developing a novel RAGE-Fc fusion protein to address critical unmet needs in inflammatory and degenerative diseases. Its lead program targets severe lung inflammation and cytokine storms associated with COVID-19, with additional preclinical programs for diabetic complications and age-related macular degeneration. The company operates as a virtual entity, leveraging external collaborators and contract research organizations to advance its pipeline with capital efficiency. As of early 2026, Galactica is in the preclinical phase, with its RAGE-Fc candidate demonstrating promising in vitro and in vivo activity against inflammatory mediators. While the therapeutic hypothesis is biologically plausible, the company remains at an early stage with significant technical and regulatory risks. The virtual model reduces overhead but relies on successful outsourcing and milestone execution. No clinical data exist, and valuation is not publicly disclosed. Given the high attrition rates in preclinical development, the conviction score is moderate. Near-term value inflection will depend on completion of IND-enabling studies and potential partnering or licensing discussions for its RAGE-Fc platform. Investors should monitor progress in de-risking the lead asset through GLP toxicology and manufacturing scale-up.

Upcoming Catalysts (preview)

• Q1 2027Completion of GLP toxicology studies for RAGE-Fc60% success
• Q2 2027Submission of IND application for lead program in COVID-19 cytokine storm40% success